MX9701996A - Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno. - Google Patents

Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno.

Info

Publication number
MX9701996A
MX9701996A MX9701996A MX9701996A MX9701996A MX 9701996 A MX9701996 A MX 9701996A MX 9701996 A MX9701996 A MX 9701996A MX 9701996 A MX9701996 A MX 9701996A MX 9701996 A MX9701996 A MX 9701996A
Authority
MX
Mexico
Prior art keywords
structuring
disorders
oxide
salt
treating collagen
Prior art date
Application number
MX9701996A
Other languages
English (en)
Inventor
Yann Mahe
Lionel Breton
Jean-Baptiste Galey
Bruno Bernard
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Publication of MX9701996A publication Critical patent/MX9701996A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe la utilizacion como substancia activa del 3-oxido de 2, 4-diamino-pirimidina o de una de sus sales fisiologicamente aceptables, para la preparacion de una composicion terapéutica. Esta composicion terapéutica está destinada al tratamiento de los desordenes de la maduracion y de la estructuracion del colágeno.
MX9701996A 1994-09-19 1995-09-19 Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno. MX9701996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9411133A FR2724561B1 (fr) 1994-09-19 1994-09-19 Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene
PCT/FR1995/001197 WO1996009048A1 (fr) 1994-09-19 1995-09-19 Utilisation du 2,4-diamino pyrimidine 3-oxyde ou de l'un de ses sels dans le traitement des desordres de la maturation et de la structuration du collagene

Publications (1)

Publication Number Publication Date
MX9701996A true MX9701996A (es) 1997-06-28

Family

ID=9467049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701996A MX9701996A (es) 1994-09-19 1995-09-19 Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno.

Country Status (22)

Country Link
US (1) US5846552A (es)
EP (1) EP0783307B1 (es)
JP (1) JP2945482B2 (es)
KR (1) KR100250939B1 (es)
CN (1) CN1070702C (es)
AT (1) ATE213414T1 (es)
AU (1) AU691336B2 (es)
BR (1) BR9508841A (es)
CA (1) CA2199995C (es)
CZ (1) CZ284476B6 (es)
DE (1) DE69525539T2 (es)
DK (1) DK0783307T3 (es)
ES (1) ES2171550T3 (es)
FI (1) FI971127A (es)
FR (1) FR2724561B1 (es)
HU (1) HU223143B1 (es)
MX (1) MX9701996A (es)
NO (1) NO311784B1 (es)
PL (1) PL186385B1 (es)
PT (1) PT783307E (es)
RU (1) RU2153874C2 (es)
WO (1) WO1996009048A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0875781B1 (en) * 1997-04-30 2005-08-17 JSR Corporation Liquid crystal alignment layer, production method for the same, and liquid crystal display device comprising the same
US7763587B2 (en) 2002-06-13 2010-07-27 L'oreal S.A. Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process
US7326717B2 (en) * 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
FR2871688B1 (fr) 2004-06-16 2008-05-16 Oreal Procede pour favoriser la penetration d'un actif et composition permettant sa mise en oeuvre
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
FR2902324B1 (fr) * 2006-06-20 2009-04-03 Oreal Utilisation d'acide ellagique pour le traitement de la canitie
EP1897533A1 (en) * 2006-09-08 2008-03-12 Revotar Biopharmaceuticals AG Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
BRPI0916690B1 (pt) 2008-07-29 2022-04-12 L'oreal Uso de uma quantidade eficaz de pelo menos um microorganismo probiótico, composição coméstica e/ou dermatólogica, método coméstico para tratar e/ou prevenir distúrbios estéticos do couro cabeludo em um indivíduo, processo cosmético para prevenir e/ou tratar uma condição de caspa do couro cabeludo, conjunto cosmético, e, uso cosmético de pelo menos uma quantidade eficaz de pelo menos um primeiro e um segundo agente cosmético ativo
FR2951938B1 (fr) 2009-10-30 2012-01-06 Oreal Utilisation d'un extrait de punica granatum pour lutter contre la canitie
CN104398418A (zh) * 2014-11-06 2015-03-11 陈爱华 一种防脱发护发素
FR3130153A1 (fr) 2021-12-15 2023-06-16 L'oreal Utilisation d’au moins un dérivé de pyrimidine 3-oxyde pour renforcer la fonction barrière de la peau

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049902A3 (en) * 1980-10-15 1982-09-01 Teijin Limited Novel thiazolo(3,2-a)pyrimidines, derivatives thereof, processes for production thereof, and pharmaceutical use thereof
FR2644460A1 (fr) * 1989-03-16 1990-09-21 Oreal Esters retinoiques de d-desosamine, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
LU87766A1 (fr) * 1990-07-20 1992-03-11 Oreal Utilisation de derives de pyrimidine 3-oxyde pour freiner la chute des cheveux et compositions topiques mises en oeuvre
CA2085954A1 (en) * 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use

Also Published As

Publication number Publication date
AU691336B2 (en) 1998-05-14
US5846552A (en) 1998-12-08
FR2724561A1 (fr) 1996-03-22
DK0783307T3 (da) 2002-06-03
DE69525539T2 (de) 2002-09-26
CN1159755A (zh) 1997-09-17
KR970705998A (ko) 1997-11-03
ES2171550T3 (es) 2002-09-16
FI971127A0 (fi) 1997-03-18
CN1070702C (zh) 2001-09-12
DE69525539D1 (de) 2002-03-28
CA2199995C (fr) 2002-01-15
CZ84297A3 (en) 1997-08-13
PL186385B1 (pl) 2004-01-30
RU2153874C2 (ru) 2000-08-10
CA2199995A1 (fr) 1996-03-28
NO311784B1 (no) 2002-01-28
NO971182L (no) 1997-05-14
BR9508841A (pt) 1999-05-04
EP0783307A1 (fr) 1997-07-16
AU3476595A (en) 1996-04-09
HU223143B1 (hu) 2004-03-29
FR2724561B1 (fr) 1996-12-13
WO1996009048A1 (fr) 1996-03-28
EP0783307B1 (fr) 2002-02-20
FI971127A (fi) 1997-03-18
PL319279A1 (en) 1997-08-04
HUT76796A (en) 1997-11-28
PT783307E (pt) 2002-07-31
NO971182D0 (no) 1997-03-14
CZ284476B6 (cs) 1998-12-16
KR100250939B1 (ko) 2000-05-01
JP2945482B2 (ja) 1999-09-06
JPH10506886A (ja) 1998-07-07
ATE213414T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
MX9701996A (es) Utlizacion de 3-oxo de 2, 4-diamino-pirimidina o una de sus sales en el tratamiento de desordenes dela maduracion y de la estructuracion del colageno.
HU9700060D0 (en) New compound, it's production and it's use as active component of a medicine
PL338673A1 (en) Application of fanquinone in treating alzheimer disease
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
BG103262A (en) Antimycotic gel with high degree of active substance release
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
AU6736096A (en) 1(hetero)aryl-4-(condensed thiazol-2-ylalkyl)-piperazine derivatives, their preparation and their use in the treatment of 5-ht1a-receptor mediated disorders
HU9500120D0 (en) Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease
NZ268039A (en) Use of efaroxan in treating parkinson's disease
GR3033332T3 (en) Biologically active ureido derivatives useful in the treatment of multiple sclerosis
AU2137595A (en) Use of arylpiperazine derivatives for the treatment of Parkinson's disease and psychosis
GR3034688T3 (en) Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
ITMI941939A0 (it) Derivati purinici ed 8-azapurinici atti al trattamento terapeutico dell'aids
AU4448497A (en) Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents
AU5870298A (en) 1,4-dihydropyridin derivatives and their use in therapy
MY107336A (en) The process for the preparation of enantiomerically pure thienopyran derivatives.
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
HUP9903490A3 (en) Substituted 4-(1h-benzimidazol-2-yl)[1,4]diazepanen derivatives useful for the treatment of allergic diseases, preparation and use thereof

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees